Table 1 Baseline demographics and outcomes in the groups receiving noble metal coated catheter or uncoated control catheter
BIP Foley n = 750 | Control n = 250 | p-value | Relative reduction (RR) (%) | |
|---|---|---|---|---|
Demographics and comorbidities | ||||
Age, mean (SD) | 48 (15) | 47 (15) | 0.0908 | NA |
Weight, mean (SD) | 65 (34) | 69 (58) | 0.27 | NA |
Height, mean (SD) | 161 (11) | 162 (9) | 0.39 | NA |
Sex, female, n (%) | 235 (31) | 101 (40) | 0.0106 | NA |
Diabetes mellitus | 46 (6.1) | 19 (7.6) | 0.4 | NA |
Cancer | 5 (0.7) | 5 (2) | 0.07 | NA |
Distribution of patients at each site and ward type | ||||
Site 1 General surgery and ICU | 102 (14) | 34 (14) | NA | NA |
Site 2 Urology | 6 (1) | 2 (1) | NA | NA |
Site 3 Urology | 96 (13) | 32 (13) | NA | NA |
Site 4 Urology | 228 (30) | 76 (30) | NA | NA |
Site 5 General surgery | 234 (31) | 78 (31) | NA | NA |
Site 6 Urology | 84 (11) | 28 (11) | NA | NA |
Total General surgery and ICU | 336 (45) | 112 (45) | NA | NA |
Total Urology | 414 (55) | 138 (55) | NA | NA |
CAUTI | ||||
CAUTI incidences (%) TOTAL | 52 (6.9) | 53 (21.2) | < 0.001 | 67% |
CAUTI/1000 catheter days TOTAL | 6.5 (52/(7987 * 10−3)) | 20.8 (53/(2551 days * 10−3)) | < 0.001 | 69% |
General surgery and ICU (site 1 and 5) CAUTI/1000 catheter days | 12.3 (32/(2612 * 10−3)) | 47.9 (37/(773 * 10−3)) | < 0.001 | 70% |
Urology (site 2–4, 6) CAUTI/1000 catheter days | 3.7 (20/5375 * 10−3)) | 9.0 (16/(1778 * 10−3)) | 0.006 | 58% |
Bacteriuria | ||||
Positive growth at inclusion TOTAL n (%) | 30 (4) | 16 (6.4) | 0.11 | NA |
Positive growth TOTAL n (%) | 209 (28) | 161 (64) | < 0.001 | 57% |
Positive growth, ≥ 105 CFU/ml n (%) | 89 (11.9) | 67 (26.8) | < 0.001 | 56% |
Positive growth, < 105 ≥ 103, CFU/ml n (%) | 66 (8.8) | 53 (21.2) | < 0.001 | 59% |
Antibiotics, catheterization days, hospital | ||||
Antibiotics prophylaxis*, days/antibiotic treated study patient | 8.2 | 8.5 | 0.54 | No significant difference |
Antibiotics prophylaxis, days/all study patients | 4.7 | 5.0 | 0.47 | No significant difference |
Duration of catheterization, days | 11.1 | 10.9 | 0.79 | No significant difference |
Duration of hospital admission, days | 6.5 | 6.3 | 0.59 | No significant difference |
Adverse events | ||||
Total number of AE (%) | 162 (21.6%) | 121 (48.4%) | < 0.001 | 55% |
Total patients with at least one AE n, | 112 (14.9%) | 80 (32.0%) | < 0.001 | 53% |